UCB to Buy Candid Therapeutics for Up to $2.2 Billion

The deal seeks to bolster the company's pipeline of experimental treatments for autoimmune and inflammatory diseases.
Open original source
The deal seeks to bolster the company's pipeline of experimental treatments for autoimmune and inflammatory diseases.
Open original source